Here's Yet Another Reason to Buy Viking Therapeutics Stock Like There's No Tomorrow

Viking Therapeutics (NASDAQ: VKTX) is a hot biotech stock thanks to the company's record of reporting good data from its cardiometabolic disease programs, and there's no sign of that reputation being tarnished.In fact, Viking just gave investors an update which firms up its status as a very promising company. Here's what it reported, and why it's another reason to buy the stock.At The Liver Meeting annual conference on Nov. 19, Viking reported some phase 2b clinical results from one of its programs, VK2809, which aims to treat metabolic dysfunction-associated steatohepatitis (MASH). After 52 weeks of treatment, across all of the dose levels tested, 69% of patients saw their MASH resolve with no further worsening of liver fibrosis (toughening of the tissue). Over the same period, 51% of the patients saw their fibrosis improve by at least one standard grade, and a large majority of patients also saw their degree of liver fat decline by more than 30%.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool